Sotera Health Co (SHC) stock
Close on Nov 16, 2026Market cap $4.64BP/E 28.5Yield –
Earnings
Sotera Health's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Sotera Health's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 23, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 3, 2026before the open | $324.89M | +4.5% | $0.20 | $0.29 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026before the open | $321.38M | +9.3% | $0.19 | $0.26 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 5, 2026before the open | $280.05M | +9.8% | $0.09 | $0.18 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 24, 2026before the open | $303.00M | +4.5% | $0.12 | $0.26 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025before the open | $311.00M | +9.1% | $0.17 | $0.26 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 8, 2025before the open | $294.00M | +6.1% | $0.03 | $0.20 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 1, 2025before the open | $255.00M | +2.8% | -$0.05 | $0.14 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025before the open | $290.00M | -6.5% | $0.04 | $0.21 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 5, 2024before the open | $285.00M | +8.4% | $0.06 | $0.17 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 5, 2024before the open | $277.00M | +8.6% | $0.03 | $0.19 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 2, 2024before the open | $248.00M | +12.2% | $0.02 | $0.13 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 27, 2024before the open | $310.00M | +23.0% | $0.14 | $0.26 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 1, 2023before the open | $263.00M | +5.6% | -$0.05 | $0.21 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023before the open | $255.00M | -4.5% | $0.08 | $0.21 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 3, 2023before the open | $221.00M | -6.8% | $0.01 | $0.13 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 28, 2023before the open | $252.00M | +4.6% | -$1.14 | $0.25 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 2, 2022before the open | $249.00M | +10.2% | $0.09 | $0.23 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022before the open | $267.00M | – | $0.11 | $0.27 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022before the open | $237.00M | – | $0.11 | $0.22 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 1, 2022before the open | $241.00M | – | $0.13 | $0.23 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021before the open | $226.00M | – | $0.10 | $0.21 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 12, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 13, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 9, 2021before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Sotera Health's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| constant currency growthnon-GAAP | FY2026 | +5.25% – +6.75% | – | New | Aug 6, 2026 |
| Net revenuesGAAP | FY2026 | $1.23B – $1.25B | $1.23B – $1.25B | Lowered | Nov 3, 2026 |
| Net revenues | FY2026 | $1.24B – $1.25B | $1.23B – $1.25B | Raised | Aug 6, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $632.00M – $641.00M | $632.00M – $641.00M | Reaffirmed | Nov 3, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $634.00M – $643.00M | $632.00M – $641.00M | Raised | Aug 6, 2026 |
| Adjusted EBITDA constant currency growthnon-GAAP | FY2026 | +5.75% – +7.25% | – | New | Aug 6, 2026 |
| Adjusted EPSnon-GAAP | FY2026 | $0.95 – $1.01 | $0.93 – $1.01 | Raised | Nov 3, 2026 |
| Adjusted EPSnon-GAAP | FY2026 | $0.95 – $1.01 | $0.93 – $1.01 | Raised | Aug 6, 2026 |
| Capital expendituresGAAP | FY2026 | $200.00M – $225.00M | $175.00M – $225.00M | Raised | Nov 3, 2026 |
| Capital expenditures | FY2026 | $200.00M – $225.00M | $175.00M – $225.00M | Raised | Aug 6, 2026 |
| A weighted-average fully diluted share countGAAP | FY2026 | 289 – 291 | – | Reaffirmed | Nov 3, 2026 |
| Interest expenseGAAP | FY2026 | $137.00M – $140.00M | $135.00M – $145.00M | Narrowed | Nov 3, 2026 |
| Interest expense | FY2026 | $135.00M – $142.00M | $135.00M – $145.00M | Lowered | Aug 6, 2026 |
| Tax rate applicable to Adjusted Net Incomenon-GAAP | FY2026 | 27% – 28% | 27% – 29% | Lowered | Nov 3, 2026 |
| Tax rate applicable to Adjusted Net Incomenon-GAAP | FY2026 | 27% – 28% | 27% – 29% | Lowered | Aug 6, 2026 |
| weighted-average fully diluted share count | FY2026 | 289 – 291 | 289 – 291 | Reaffirmed | Aug 6, 2026 |
| weighted-average fully diluted share countGAAP | FY2026 | 289 – 291 | – | New | Feb 24, 2026 |
Guidance vs results
The last range Sotera Health gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Adjusted EPS | $0.81 – $0.86 | $0.86Σ4Q | Within range |
| FY2025 | Revenue | $1.16B | $1.16BΣ4Q | Above range |
| FY2025 | Revenue growth | +5.5% | +5.73%Σ4Q | Above range |
Guidance history
Every forecast Sotera Health put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 3, 2026 | Capital expenditures | FY2026 | $200.00M – $225.00M | Raised |
| Nov 3, 2026 | Adjusted EBITDA | FY2026 | $632.00M – $641.00M | Reaffirmed |
| Nov 3, 2026 | Adjusted EPS | FY2026 | $0.95 – $1.01 | Raised |
| Nov 3, 2026 | A weighted-average fully diluted share count | FY2026 | 289 – 291 | Reaffirmed |
| Nov 3, 2026 | Tax rate applicable to Adjusted Net Income | FY2026 | 27% – 28% | Lowered |
| Nov 3, 2026 | Interest expense | FY2026 | $137.00M – $140.00M | Narrowed |
| Nov 3, 2026 | Net revenues | FY2026 | $1.23B – $1.25B | Lowered |
| Aug 6, 2026 | Capital expenditures | FY2026 | $200.00M – $225.00M | Raised |
| Aug 6, 2026 | Adjusted EBITDA constant currency growth | FY2026 | +5.75% – +7.25% | New |
| Aug 6, 2026 | Adjusted EBITDA | FY2026 | $634.00M – $643.00M | Raised |
| Aug 6, 2026 | Adjusted EPS | FY2026 | $0.95 – $1.01 | Raised |
| Aug 6, 2026 | weighted-average fully diluted share count | FY2026 | 289 – 291 | Reaffirmed |
| Aug 6, 2026 | Tax rate applicable to Adjusted Net Income | FY2026 | 27% – 28% | Lowered |
| Aug 6, 2026 | Interest expense | FY2026 | $135.00M – $142.00M | Lowered |
| Aug 6, 2026 | constant currency growth | FY2026 | +5.25% – +6.75% | New |
| Aug 6, 2026 | Net revenues | FY2026 | $1.24B – $1.25B | Raised |
| May 5, 2026 | Capital expenditures | FY2026 | $175.00M – $225.00M | New |
| May 5, 2026 | Adjusted EBITDA | FY2026 | $632.00M – $641.00M | New |
| May 5, 2026 | Adjusted EPS | FY2026 | $0.93 – $1.01 | New |
| May 5, 2026 | weighted-average fully diluted share count | FY2026 | 289 – 291 | New |
| May 5, 2026 | Tax rate applicable to Adjusted Net Income | FY2026 | 27% – 29% | New |
| May 5, 2026 | Interest expense | FY2026 | $135.00M – $145.00M | New |
| May 5, 2026 | Net revenues | FY2026 | $1.23B – $1.25B | New |
| Feb 24, 2026 | Capital expenditures | FY2026 | $175.00M – $225.00M | New |
| Feb 24, 2026 | Adjusted EBITDA | FY2026 | $632.00M – $641.00M | New |
| Feb 24, 2026 | Adjusted EPS | FY2026 | $0.93 – $1.01 | New |
| Feb 24, 2026 | weighted-average fully diluted share count | FY2026 | 289 – 291 | New |
| Feb 24, 2026 | Tax rate applicable to Adjusted Net Income | FY2026 | 27% – 29% | New |
| Feb 24, 2026 | Interest expense | FY2026 | $135.00M – $145.00M | New |
| Feb 24, 2026 | Net revenues | FY2026 | $1.23B – $1.25B | New |
| Jan 12, 2026 | revenue | FY2025 | +5.5% | New |
| Jan 12, 2026 | revenue on a constant-currency basis | FY2025 | +5% | Narrowed |
| Jan 12, 2026 | revenue | FY2025 | $1.16B | New |
| Nov 4, 2025 | Capital expenditures | FY2025 | $125.00M – $135.00M | New |
| Nov 4, 2025 | Adjusted EBITDA growth | FY2025 | +6.75% – +7.75% | New |
| Nov 4, 2025 | Adjusted EPS | FY2025 | $0.81 – $0.86 | New |
| Nov 4, 2025 | weighted-average fully diluted share count | FY2025 | 286 – 287 | New |
| Nov 4, 2025 | Tax rate applicable to Adjusted Net Income | FY2025 | 29% – 31% | New |
| Nov 4, 2025 | Interest Expense | FY2025 | $154.00M – $158.00M | New |
| Nov 4, 2025 | Net revenues growth | FY2025 | +4.5% – +6% | New |
| Aug 8, 2025 | Capital expenditures | FY2025 | $170.00M – $180.00M | Lowered |
| Aug 8, 2025 | Adjusted EBITDA growth | FY2025 | +6% – +7.5% | Raised |
| Aug 8, 2025 | Adjusted EPS | FY2025 | $0.75 – $0.82 | Raised |
| Aug 8, 2025 | weighted-average fully diluted share count | FY2025 | 286 – 287 | Reaffirmed |
| Aug 8, 2025 | Tax rate applicable to Adjusted Net Income | FY2025 | 31.5% – 33.5% | Lowered |
| Aug 8, 2025 | Interest Expense | FY2025 | $155.00M – $165.00M | Reaffirmed |
| Aug 8, 2025 | Net revenues growth | FY2025 | +4.5% – +6% | Raised |
| May 1, 2025 | Capital expenditures | FY2025 | $190.00M – $210.00M | New |
| May 1, 2025 | Adjusted EBITDA growth | FY2025 | +4.5% – +6.5% | Reaffirmed |
| May 1, 2025 | Adjusted EPS | FY2025 | $0.70 – $0.76 | Reaffirmed |
| May 1, 2025 | weighted-average fully diluted share count | FY2025 | 286 – 287 | Reaffirmed |
| May 1, 2025 | Interest Expense | FY2025 | $155.00M – $165.00M | New |
| May 1, 2025 | Tax rate applicable to Adjusted Net Income | FY2025 | 33% – 35% | Reaffirmed |
| May 1, 2025 | Net revenues growth | FY2025 | +4% – +6% | Reaffirmed |
| Feb 27, 2025 | Capital expenditures | FY2025 | $190.00M – $210.00M | New |
| Feb 27, 2025 | Adjusted EBITDA growth | FY2025 | +4.5% – +6.5% | New |
| Feb 27, 2025 | Adjusted EPS | FY2025 | $0.70 – $0.76 | New |
| Feb 27, 2025 | Tax rate applicable to Adjusted Net Income | FY2025 | 33% – 35% | New |
| Feb 27, 2025 | Interest expense | FY2025 | $155.00M – $165.00M | New |
| Feb 27, 2025 | weighted-average fully diluted share count | FY2025 | 286 – 287 | New |
| Feb 27, 2025 | Foreign currency headwind to net revenues | FY2025 | 2.25% | New |
| Feb 27, 2025 | Foreign currency headwind to Adjusted EBITDA | FY2025 | 2.5% | Raised |
| Feb 27, 2025 | Net revenues growth | FY2025 | +4% – +6% | New |
| Nov 5, 2024 | Capital expenditures | FY2024 | $175.00M – $185.00M | Lowered |
| Nov 5, 2024 | Adjusted EBITDA growth | FY2024 | +4% – +6% | Reaffirmed |
| Nov 5, 2024 | Adjusted EPS | FY2024 | $0.67 – $0.75 | Reaffirmed |
| Nov 5, 2024 | Tax rate applicable to Adjusted Net Income | FY2024 | 31.5% – 34.5% | Reaffirmed |
| Nov 5, 2024 | Interest Expense | FY2024 | $165.00M – $175.00M | Reaffirmed |
| Nov 5, 2024 | weighted-average fully diluted share count | FY2024 | 283 – 285 | Reaffirmed |
| Nov 5, 2024 | Net revenues growth | FY2024 | +4% – +6% | New |
| Aug 5, 2024 | Capital expenditures | FY2024 | $205.00M – $225.00M | New |
| Aug 5, 2024 | Adjusted EBITDA | FY2024 | +4% – +6% | Reaffirmed |
| Aug 5, 2024 | Adjusted EPS | FY2024 | $0.67 – $0.75 | Reaffirmed |
| Aug 5, 2024 | weighted-average fully diluted share count | FY2024 | 283 – 285 | Reaffirmed |
| Aug 5, 2024 | Tax rate applicable to Adjusted Net Income | FY2024 | 31.5% – 34.5% | Reaffirmed |
| Aug 5, 2024 | Interest Expense | FY2024 | $165.00M – $175.00M | New |
| Aug 5, 2024 | Net revenues | FY2024 | +4% – +6% | Reaffirmed |
| May 2, 2024 | Capital expenditures | FY2024 | $205.00M – $225.00M | Reaffirmed |
| May 2, 2024 | Adjusted EBITDA | FY2024 | +4% – +6% | Reaffirmed |
| May 2, 2024 | Adjusted EPS | FY2024 | $0.67 – $0.75 | Reaffirmed |
| May 2, 2024 | weighted-average fully diluted share count | FY2024 | 283 – 285 | New |
| May 2, 2024 | Tax rate applicable to Adjusted Net Income | FY2024 | 31.5% – 34.5% | Reaffirmed |
| May 2, 2024 | Interest Expense | FY2024 | $170.00M – $180.00M | Reaffirmed |
| May 2, 2024 | Net revenues | FY2024 | +4% – +6% | Reaffirmed |
| Feb 27, 2024 | Capital expenditures | FY2024 | $205.00M – $225.00M | New |
| Feb 27, 2024 | Adjusted EBITDA | FY2024 | +4% – +6% | New |
| Feb 27, 2024 | Adjusted EPS | FY2024 | $0.67 – $0.75 | New |
| Feb 27, 2024 | weighted-average fully diluted share count | FY2024 | 283 – 285 | New |
| Feb 27, 2024 | Tax rate applicable to Adjusted Net Income | FY2024 | 31.5% – 34.5% | New |
| Feb 27, 2024 | Interest Expense | FY2024 | $170.00M – $180.00M | New |
| Feb 27, 2024 | Net revenues | FY2024 | +4% – +6% | New |
| Nov 1, 2023 | Capital expenditures | FY2023 | $200.00M – $215.00M | Reaffirmed |
| Nov 1, 2023 | Adjusted EBITDA | FY2023 | $520.00M – $535.00M | Reaffirmed |
| Nov 1, 2023 | Adjusted EPS | FY2023 | $0.78 – $0.86 | Reaffirmed |
| Nov 1, 2023 | A fully diluted share count | FY2023 | 283 – 285 | Reaffirmed |
| Nov 1, 2023 | Net Leverage Ratio | FY2023 | 4 | Reaffirmed |
| Nov 1, 2023 | The tax rate applicable to Adjusted Net Income | FY2023 | 30% – 32% | Reaffirmed |
| Nov 1, 2023 | Net revenues | FY2023 | $1.04B – $1.06B | Reaffirmed |
| Aug 3, 2023 | Capital expenditures | FY2023 | $200.00M – $215.00M | Raised |
| Aug 3, 2023 | Adjusted EBITDA | FY2023 | $520.00M – $535.00M | Lowered |
| Aug 3, 2023 | Adjusted EPS | FY2023 | $0.78 – $0.86 | Reaffirmed |
| Aug 3, 2023 | fully diluted share count | FY2023 | 283 – 285 | Reaffirmed |
| Aug 3, 2023 | Net Leverage Ratio | FY2023 | 4 | Raised |
| Aug 3, 2023 | Tax rate applicable to Adjusted Net Income | FY2023 | 30% – 32% | Lowered |
| Aug 3, 2023 | Net revenues | FY2023 | $1.04B – $1.06B | Lowered |
| May 3, 2023 | Capital expenditures | FY2023 | $185.00M – $215.00M | New |
| May 3, 2023 | Adjusted EBITDA | FY2023 | $530.00M – $550.00M | Reaffirmed |
| May 3, 2023 | Adjusted EPS | FY2023 | $0.78 – $0.86 | Reaffirmed |
| May 3, 2023 | fully diluted share count | FY2023 | 283 – 285 | Reaffirmed |
| May 3, 2023 | 2023 year-end Net Leverage Ratio | FY2023 | 2 – 4 | Reaffirmed |
| May 3, 2023 | Tax rate applicable to Adjusted Net Income | FY2023 | 30% – 33% | Reaffirmed |
| May 3, 2023 | Net revenues | FY2023 | $1.06B – $1.09B | Reaffirmed |
| Feb 28, 2023 | Capital expenditures | FY2023 | $185.00M – $215.00M | New |
| Feb 28, 2023 | Adjusted EBITDA | FY2023 | $530.00M – $550.00M | New |
| Feb 28, 2023 | Adjusted EPS | FY2023 | $0.78 – $0.86 | New |
| Feb 28, 2023 | fully diluted share count | FY2023 | 283 – 285 | New |
| Feb 28, 2023 | Net Leverage Ratio | FY2023 | 2 – 4 | New |
| Feb 28, 2023 | Tax rate applicable to Adjusted Net Income | FY2023 | 30% – 33% | New |
| Feb 28, 2023 | Net revenues | FY2023 | $1.06B – $1.09B | New |
| Nov 2, 2022 | Capital expenditures | FY2022 | $150.00M – $170.00M | Raised |
| Nov 2, 2022 | Adjusted EBITDA | FY2022 | $500.00M – $510.00M | Lowered |
| Nov 2, 2022 | Adjusted EPS | FY2022 | $0.91 – $0.95 | Lowered |
| Nov 2, 2022 | Fully diluted share count | FY2022 | 280 – 282 | Reaffirmed |
| Nov 2, 2022 | Net leverage reduction | FY2022 | 3.2 – 3.3 | New |
| Nov 2, 2022 | Tax rate applicable to Adjusted Net Income | FY2022 | 28% | Lowered |
| Aug 4, 2022 | Capital expenditures | FY2022 | $140.00M – $170.00M | Reaffirmed |
| Aug 4, 2022 | Adjusted EBITDA | FY2022 | $515.00M – $525.00M | Lowered |
| Aug 4, 2022 | Adjusted EPS | FY2022 | $0.93 – $0.97 | Lowered |
| Aug 4, 2022 | fully diluted share count | FY2022 | 280 – 282 | Reaffirmed |
| Aug 4, 2022 | Tax rate applicable to Adjusted Net Income | FY2022 | 29% – 30% | Reaffirmed |
| Aug 4, 2022 | Net revenues | FY2022 | $1.00B – $1.02B | Lowered |
| May 5, 2022 | Capital expenditures | FY2022 | $140.00M – $170.00M | Reaffirmed |
| May 5, 2022 | Adjusted EBITDA | FY2022 | $515.00M – $535.00M | Reaffirmed |
| May 5, 2022 | Adjusted EPS | FY2022 | $0.93 – $0.99 | Reaffirmed |
| May 5, 2022 | fully diluted share count | FY2022 | 280 – 282 | Reaffirmed |
| May 5, 2022 | Tax rate applicable to Adjusted Net Income | FY2022 | 29% – 30% | Reaffirmed |
| May 5, 2022 | Net revenues | FY2022 | $1.00B – $1.03B | Reaffirmed |
| Mar 1, 2022 | Capital expenditures | FY2022 | $140.00M – $170.00M | New |
| Mar 1, 2022 | Adjusted EBITDA | FY2022 | $515.00M – $535.00M | New |
| Mar 1, 2022 | Adjusted EPS | FY2022 | $0.93 – $0.99 | New |
| Mar 1, 2022 | fully diluted share count | FY2022 | 280 – 282 | New |
| Mar 1, 2022 | Tax rate applicable to Adjusted Net Income | FY2022 | 29% – 30% | New |
| Mar 1, 2022 | Net revenues | FY2022 | $1.00B – $1.03B | New |
| Nov 10, 2021 | Capital expenditures | FY2021 | $90.00M – $100.00M | New |
| Nov 10, 2021 | Adjusted EBITDA | FY2021 | $475.00M – $480.00M | New |
| Nov 10, 2021 | Adjusted EPS | FY2021 | $0.87 – $0.88 | New |
| Nov 10, 2021 | Fully diluted share count | FY2021 | 279 – 280 | New |
| Nov 10, 2021 | Tax rate applicable to Adjusted Net Income | FY2021 | 28% | New |
| Nov 10, 2021 | Net revenues | FY2021 | $920.00M – $930.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Sotera Health filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- News
- Update
- Results
- Results
- Update
See a number that looks wrong?